Orum Therapeutics
About Orum Therapeutics
Orum Therapeutics is a private biotech company located in Cambridge, Massachusetts, US and Daejeon, Korea. We are developing a novel class of therapeutics to bring new medicines to patients with unmet medical needs. Orum leverages its proprietary antibody-drug conjugate platforms to inhibit or degrade intracellular target proteins. We are advancing our first set of oncology candidates toward preclinical development.
5 articles with Orum Therapeutics
-
Orum Therapeutics Announces $30 Million Series B Financing to Advance Cell-Penetrating, Cell-Specific Antibody Technology for Novel Therapeutics
7/17/2019
Financing proceeds to fund further platform development and therapeutic discovery in cancer and rare diseases, and expansion of Orum’s new Boston R&D labs
-
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
-
Orum Therapeutics Raises $8 Million Series A Financing To Advance Cell-Penetrating Antibody Technology For Novel Cancer Therapeutics
6/14/2017
-
Orum Therapeutics Release: Cell-Penetrating Antibodies To Oncogenic RAS Show Anti-Tumor Activity
5/10/2017
-
Orum Therapeutics Selected For South Korea's Prestigious Tech Incubator Program For Startup
12/21/2016